Clin2
NCT06414499Possibly a fitRecruiting

Tenecteplase for mild stroke within 4.5 hours

Minor Ischemic Stroke

Treatments studied

Part of Brain & nervous system clinical trials.

This trial tests a clot-busting drug called tenecteplase for patients having a mild stroke (with weakness on one side or trouble speaking) who can get treatment within 4.5 hours. The goal is to see if this drug helps improve blood flow and reduces disability.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
1,386 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be at least 18 years old and have had a mild stroke (NIHSS score 5 or lower) that causes weakness on one side or trouble speaking.
  • Your symptoms must have started less than 4.5 hours ago (the time you were last seen well).
  • You must be able to walk and take care of yourself before the stroke (modified Rankin score 0 or 1).
  • You should not have had any bleeding problems, recent surgeries, or certain blood thinners that could raise the risk of bleeding.
  • You must not have a large stroke or certain brain conditions like a tumor or recent head injury.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT07357987Recruiting· Phase 3
Stroke treatment with tenecteplase via artery

This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.

Beijing, Beijing Municipality
NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07201688Recruiting· Phase 3
Extending the window for stroke clot-busting drug

This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.

Puyang, Henan
NCT06010628Recruiting· Phase 4
Tenecteplase for stroke 4.5 to 6 hours after onset

This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.

Shenyang, None Selected
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires

Hear when a new Minor Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.